Social Europe

politics, economy and employment & labour

  • Themes
    • European digital sphere
    • Recovery and resilience
  • Publications
    • Books
    • Dossiers
    • Occasional Papers
    • Research Essays
    • Brexit Paper Series
  • Podcast
  • Videos
  • Newsletter

Next steps for a people’s vaccine

Jayati Ghosh 10th May 2021

Ending the pandemic requires not only an intellectual-property rights waiver but scaling up knowledge transfer and public production of vaccine supplies.

people's vaccine
Jayati Ghosh

The decision by Joe Biden’s administration to stop opposing a proposed Covid-19 waiver of certain intellectual-property rights under World Trade Organization rules is a welcome move. The United States trade representative, Katherine Tai, acknowledges that ‘the extraordinary circumstances of the Covid-19 pandemic call for extraordinary measures’. While affirming that it ‘believes strongly in intellectual property protections’, the Biden administration ‘in service of ending this pandemic, supports the waiver of those protections for Covid-19 vaccines’. Already, the US decision may be persuading other rich-country hold-outs in Europe and elsewhere to follow suit.

While the rapid development of Covid-19 vaccines was a truly impressive achievement, it has been tarnished by constraints on global vaccine supply and the related inequities in distribution. As of May 4th, less than 8 per cent of the world’s population had received even one dose of any Covid-19 vaccine, while just ten rich countries accounted for 80 per cent of all vaccinations. The reason is not just that rich countries have been buying up all available doses—there also simply have not been enough doses to go around.

Largely artificial

But this scarcity itself is largely artificial. Vaccine production has been limited by pharmaceutical companies’ refusal to share knowledge and technology. Though the companies producing the approved vaccines have benefited from public subsidies and publicly-funded research, they nonetheless have taken advantage of patent protections to maintain a monopoly, limiting production to their own factories and a select few other companies to whom they have granted licences.

These patents are enshrined and enforced internationally through the WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which allows for action to be taken against countries that provide compulsory licenses allowing ‘someone else to produce a patented product or process without the consent of the patent owner’. It is this threat of legal action that led a majority of WTO members to propose a temporary waiver for Covid-19 drugs, vaccines, diagnostics and other technologies needed to fight the pandemic. And yet, even this minor step has been blocked in the WTO TRIPS Council, because (mostly) rich countries have been prioritising big pharmaceutical companies’ interests over global health.

Our job is keeping you informed!


Subscribe to our free newsletter and stay up to date with the latest Social Europe content.


We will never send you spam and you can unsubscribe anytime.

Thank you!

Please check your inbox and click on the link in the confirmation email to complete your newsletter subscription.

.

A waiver has become all the more urgent with the coronavirus on the rampage across south America and India, where a near-complete breakdown of overstretched health services is resulting in a catastrophic loss of life. Worse, the rapid spread of the virus has already given rise to dangerous new variants. We absolutely must vaccinate as many people as possible before vaccine-resistant variants emerge.

Temporarily waiving IP rights is essential, but it is only the first step. A waiver agreement would address the previously insurmountable legal side of the problem. But much more will need to be done to make a ‘people’s vaccine’ universally available as soon as possible.

Sharing technology

The next step is to push for concrete measures to facilitate the transfer of knowledge and technology. From Canada to Bangladesh, many potential vaccine producers with the required facilities have so far been denied the licences and technical know-how to proceed. Not a single pharmaceutical company has joined the World Health Organization’s voluntary facility for sharing technology, the Covid-19 Technology Access Pool (C-TAP).

Governments in the US, Europe and elsewhere, having given large subsidies to develop the approved vaccines, can and should press the companies to share the knowledge that public money helped provide. We know this can be done, because the Biden administration has already persuaded Johnson & Johnson to share its technology with Merck to boost domestic production of its single-dose vaccine. Surely the other companies that have benefited from public support could be pressed to do the same with producers around the world.

In the meantime, the TRIPS waiver could increase vaccine production in other ways as well. Moderna, which relied almost completely on US government funding, has already declared that it will not enforce its patent. But its messenger-RNA vaccine uses some knowledge that it has licensed (and paid for) from other companies, which could in turn sue any other producer using the same technology.


We need your support


Social Europe is an independent publisher and we believe in freely available content. For this model to be sustainable, however, we depend on the solidarity of our readers. Become a Social Europe member for less than 5 Euro per month and help us produce more articles, podcasts and videos. Thank you very much for your support!

Become a Social Europe Member

The TRIPS waiver would eliminate this possibility, allowing production to be scaled up rapidly. With Moderna now indicating that it will produce three billion doses in 2022 alone, the mRNA vaccines are apparently quite amenable to expanded production. They are also said to be easily adapted to account for new variants.

Public production

The case for public production of such vaccines is clear. ‘For less than the US government spends on the Covid-19 response daily,’ notes the health advocacy organisation PrEP4All, ‘it can build a facility to produce enough mRNA vaccine manufacturing capacity to vaccinate the entire world in one year, with each dose costing only $2.’

The case for public production becomes even stronger when one considers that private vaccine producers have little financial incentive to meet current global needs. Once the pandemic is contained, the demand for vaccines is likely to revert to much lower ‘normal’ levels. To win the race against the virus, we must build and deploy public manufacturing capacities in the US and other countries. And when Covid-19 is brought to heel, these facilities should be maintained for future pandemics.

The world desperately needs the TRIPS waiver and stronger measures to ensure the transfer of knowledge and technology to produce Covid-19 vaccines. But we also need to start preparing for equally exceptional circumstances in the future. The knowledge on which our health and prosperity depend must be both publicly funded and publicly disseminated.

Republication forbidden—copyright Project Syndicate 2021, ‘Next steps for a people’s vaccine’

Jayati Ghosh

Jayati Ghosh teaches economics at the University of Massachusetts, having done so at Jawaharlal Nehru University for 34 years. She is executive secretary of International Development Economics Associates and a member of the Independent Commission for the Reform of International Corporate Taxation.

Home ・ Most popular ・ Next steps for a people’s vaccine

Most Popular Posts

schools,Sweden,Swedish,voucher,choice Sweden’s schools: Milton Friedman’s wet dreamLisa Pelling
world order,Russia,China,Europe,United States,US The coming world orderMarc Saxer
south working,remote work ‘South working’: the future of remote workAntonio Aloisi and Luisa Corazza
Russia,Putin,assets,oligarchs Seizing the assets of Russian oligarchsBranko Milanovic
Russians,support,war,Ukraine Why do Russians support the war against Ukraine?Svetlana Erpyleva

Most Recent Posts

Gazprom,Putin,Nordstream,Putin,Schröder How the public loses out when politicians cash inKatharina Pistor
defence,europe,spending Ukraine and Europe’s defence spendingValerio Alfonso Bruno and Adriano Cozzolino
North Atlantic Treaty Organization,NATO,Ukraine The Ukraine war and NATO’s renewed credibilityPaul Rogers
transnational list,European constituency,European elections,European public sphere A European constituency for a European public sphereDomènec Ruiz Devesa
hydrogen,gas,LNG,REPowerEU EU hydrogen targets—a neo-colonial resource grabPascoe Sabido and Chloé Mikolajczak

Other Social Europe Publications

The transatlantic relationship
Women and the coronavirus crisis
RE No. 12: Why No Economic Democracy in Sweden?
US election 2020
Corporate taxation in a globalised era

Eurofound advertisement

Living and working in Europe 2021

The Covid-19 pandemic continued to be a defining force in 2021, and Eurofound continued its work of examining and recording the many and diverse impacts across the EU. Living and working in Europe 2021 provides a snapshot of the changes to employment, work and living conditions in Europe. It also summarises the agency’s findings on issues such as gender equality in employment, wealth inequality and labour shortages. These will have a significant bearing on recovery from the pandemic, resilience in the face of the war in Ukraine and a successful transition to a green and digital future.


AVAILABLE HERE

Foundation for European Progressive Studies Advertisement

EU Care Atlas: a new interactive data map showing how care deficits affect the gender earnings gap in the EU

Browse through the EU Care Atlas, a new interactive data map to help uncover what the statistics are often hiding: how care deficits directly feed into the gender earnings gap.

While attention is often focused on the gender pay gap (13%), the EU Care Atlas brings to light the more worrisome and complex picture of women’s economic inequalities. The pay gap is just one of three main elements that explain the overall earnings gap, which is estimated at 36.7%. The EU Care Atlas illustrates the urgent need to look beyond the pay gap and understand the interplay between the overall earnings gap and care imbalances.


BROWSE THROUGH THE MAP

Hans Böckler Stiftung Advertisement

Towards a new Minimum Wage Policy in Germany and Europe: WSI minimum wage report 2022

The past year has seen a much higher political profile for the issue of minimum wages, not only in Germany, which has seen fresh initiatives to tackle low pay, but also in those many other countries in Europe that have embarked on substantial and sustained increases in statutory minimum wages. One key benchmark in determining what should count as an adequate minimum wage is the threshold of 60 per cent of the median wage, a ratio that has also played a role in the European Commission's proposals for an EU-level policy on minimum wages. This year's WSI Minimum Wage Report highlights the feasibility of achieving minimum wages that meet this criterion, given the political will. And with an increase to 12 euro per hour planned for autumn 2022, Germany might now find itself promoted from laggard to minimum-wage trailblazer.


FREE DOWNLOAD

ETUI advertisement

Bilan social / Social policy in the EU: state of play 2021 and perspectives

The new edition of the Bilan social 2021, co-produced by the European Social Observatory (OSE) and the European Trade Union Institute (ETUI), reveals that while EU social policy-making took a blow in 2020, 2021 was guided by the re-emerging social aspirations of the European Commission and the launch of several important initiatives. Against the background of Covid-19, climate change and the debate on the future of Europe, the French presidency of the Council of the EU and the von der Leyen commission must now be closely scrutinised by EU citizens and social stakeholders.


AVAILABLE HERE

About Social Europe

Our Mission

Article Submission

Membership

Advertisements

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641

Social Europe Archives

Search Social Europe

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Follow us on social media

Follow us on Facebook

Follow us on Twitter

Follow us on LinkedIn

Follow us on YouTube